Skip to main content
. 2018 Jun 19;9(47):28702–28716. doi: 10.18632/oncotarget.25614

Figure 7. CTLA-4 blockade potentiates the regression of NDV-treated and distant tumors.

Figure 7

Animals bearing bilateral flank MB49 bladder tumors were treated with 4 injections of NDV administered every other day into right tumor combined with concomitant intraperitoneal injection of aCTLA-4 antibodies or PBS. (A) Treatment schema. (B) Overall Survival. (C) Growth of individual treated and distant tumors. (D) Mean tumor volumes. Tumor growth curves stop at the time of first animal death in each group. Statistical comparisons were performed at the time of first animal death in NDV and CTLA-4 group (day 25). Error bars represent standard error of the mean. Data demonstrate representative results from one of two independent experiments with 5–10 animals per group). **p < 0.01.